Alimera Sciences Inc

Alimera Sciences — Q2 2018 Earnings Presentation

11 slides from Alimera Sciences's earnings presentation, Jul 30, 2018

  1. Slide 1: Second Quarter 2018 Earnings Presentation

    Exhibit 99.2 Second Quarter 2018 Earnings Presentation Tuesday, July 31 2018

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the potential approval and commercialization of ILUVIEN for the treatment of posterior uveitis in Europe and that

  3. Slide 3: Second Quarter 2018 Overview

    Second Quarter 2018 Overview $10.9M • Record Net Revenue of $10.9 $10.4M Million • Record U.S. end user demand • International net revenue grew 26% 2Q17 2Q18 Revenue © 2018 Alimera Sciences | NASDAQ: ALIM 3

  4. Slide 4: U.S. Distributor Orders and End User Demand

    U.S. Distributor Orders and End User Demand • Historical inconsistency 1200 between distributor orders 1004 and end user demand* 1000 980 960 955 896 873 850 864 851 853 827 837 • In 2Q17, revenue units sold 804 800 777 788 750 to Alimera’s distributors 705 exceeded end user demand 608 by 15% 600 53

  5. Slide 5: U.S. End User Demand

    U.S. End User Demand 1200 1000 955 896 851 850 837 827 800 777 788 705 600 533 536 502 467 400 200 167 0 First Quarter Second Quarter Third Quarter Fourth Quarter 2015 2016 2017 2018 © 2018 Alimera Sciences | NASDAQ: ALIM 5

  6. Slide 6: Growth in ILUVIEN Usage in United States

    Growth in ILUVIEN Usage in United States 22% ~ Cumulative Eyes Treated with ILUVIEN - U.S. Growth YTD 10000 9000 8000 7000 6000 5000 4000 3000 2000 1000 0 © 2018 Alimera Sciences | NASDAQ: ALIM 6

  7. Slide 7: Income Statement

    Income Statement Three Months Ended Three Months Ended Six Months Ended June Six Months Ended June ($000’s) June 30, 2018 June 30, 2017 30, 2018 30, 2017 Revenue $10,917 $10,368 $20,719 $16,986 Operating $12,582 $10,977 $25,877 $22,519 Expenses Net Loss ($4,000) ($2,757) ($11,684) ($9,492) Adj. EBIT

  8. Slide 8: Second Quarter 2018 Overview

    Second Quarter 2018 Overview $10.9M • Record Net Revenue of $10.9 $10.4M Million • Record U.S. end user demand • International net revenue grew 26% 2Q17 2Q18 Revenue © 2018 Alimera Sciences | NASDAQ: ALIM 8

  9. Slide 9: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Loss to NON-GAAP Adjusted EBITDA Alimera believes that the non-GAAP financial information provided in this presentation can assist investors in the overall understanding of its financial performance when considered together with GAAP figures. This presentation contains a d

  10. Slide 10: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA

    Reconciliation of GAAP Net Loss to NON-GAAP Adjusted EBITDA Three Months Ended June 30, Six Months Ended June 30, ($000’s) 2018 2017 2018 2017 GAAP Net Loss ($4,000) ($2,757) ($11,684) ($9,492) Adjustments to Net Loss Interest Expense, Net and Other $1,178 $1,384 $2,329 $2,721 Provision for Taxes $7

  11. Slide 11: Tuesday, July 2018

    Second Quarter 2018 Earnings Presentation Tuesday, July 31 2018

Alimera Sciences — Q2 2018 Earnings Presentation on 6ix